Neurodevelopmental Disorders: Attention‐Deficit/Hyperactivity Disorder

Innovate to Elevate: The Latest in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutic Care

“…A combination of serdexmethylphenidate (SDX; an extended duration prodrug of dexmethylphenidate) and dexmethylphenidate (d-MPH) in a 70/30 molar ratio, classified as the Schedule IV drug by the US Drug Enforcement Administration (DEA), may be of benefit to subjects with an increased risk of abuse. 7…”

“…However, these do have merit in augmenting the response in individuals with ADHD who are not showing an adequate response to pharmacotherapy and even as an alternative to medications. 7…”

“…6 Additionally, stimulants are classified as Schedule II drugs as they have ‘a high potential for abuse’ and carry the risk of diversion (unlawful transfer of prescription medication from their licit medical purpose to the illicit marketplace), which is now becoming an increasingly prevalent problem. 7…”

Zebrafish as a Model of Neurodevelopmental Disorders

“…The etiology of NDDs is multi-factorial, complex and poorly understood (Gathercole SE et al, 2006;Krakowiak P et al, 2012;Lewis DA and Levitt PJAron, 2002;Newcorn JH et al, 2015;Thapar A,Cooper M and Rutter MJTLP, 2017). For instance, ADHD is associated with complications at birth, as well as genetic and environmental factors (e.g., chemical exposure or drug intake during gestation) (Lou HJAP, 1996;Millichap JGJP, 2008;Nigg JTJJoCC and Psychology A, 2012;Thapar A et al, 2013).…”